Private equity anesthesia groups: what hospitals should know

Your anesthesia group's letterhead changed this year. The clinicians in your rooms are the same, but the entity that signs your contract is now part of a regional platform backed by a private equity firm, and your renewal conversation runs through a regional negotiator instead of a local partner. Or you ran a request for proposals and got one credible bid, from the same consolidated group that already covers three other hospitals in your market.

Neither situation is unusual, and neither is automatically a problem. But a consolidated group changes the negotiation in ways your team should understand before the next renewal, not during it.

What changed when the ownership changed

Anesthesia has consolidated faster than most physician specialties over the past decade and a half. A database tracking ownership of anesthesia and emergency medicine groups found that private equity and publicly traded companies controlled 3.2% of the national anesthesia market in 2009 and 18.8% by 2019, a roughly sixfold increase, with the steepest growth between 2014 and 2016. In some states the share was far higher: 36% of the Texas market and 30% each in Nevada and Colorado were private-equity owned by 2019. Over the same decade, the share of Americans living in a highly concentrated anesthesia market, measured by the index the FTC uses in merger review, rose from 16.8% to 34.4%.¹

The economics are not a secret. A physician-practice-management publication describes the model plainly: firms that acquire physician groups generate returns by consolidating practices to cut costs and grow the platform, then selling it within a several-year window.² Spreading billing, credentialing and scheduling infrastructure across many locations can lower overhead per site. Whether that reaches your subsidy line depends on how the deal is structured, and how much revenue growth comes from scale versus higher unit prices.

The FTC's case against U.S. Anesthesia Partners

The clearest public test of what consolidation can do is a federal antitrust case. Its parties are named here because a federal complaint and its rulings are public record.

The FTC sued U.S. Anesthesia Partners (USAP) and the private equity firm that created it, Welsh, Carson, Anderson & Stowe, on September 21, 2023, alleging a three-part strategy: buying up nearly every large anesthesia practice in Texas, entering price-setting arrangements with practices it did not acquire, and securing an agreement with another large provider to stay out of USAP's territory. The complaint alleged this made USAP the dominant anesthesia provider in Houston, Dallas and other Texas metros, stating that "USAP's size and prices now dwarf those of its rivals," and that Texans pay tens of millions of dollars more each year for anesthesia than before USAP existed.³ According to a law firm's summary of the complaint, the FTC alleged that USAP targeted practices with existing exclusive hospital contracts, such as Capitol Anesthesiology Association, and then applied its own higher negotiated rates to the acquired practice's hospitals through a "tuck-in" clause. The complaint's theory rests on a point every hospital executive will recognize: hospitals rarely switch anesthesia coverage once it is in place.⁴

Date	Development
September 21, 2023	FTC files suit against USAP and Welsh Carson.3
May 13, 2024	Court dismisses the claims against Welsh Carson as a minority investor; the case against USAP itself proceeds to discovery.5
January 17, 2025	FTC announces a settlement with Welsh Carson: it must cap its USAP stake, drop to one non-chair board seat, and give the FTC 30 days' notice before other hospital-based physician practice deals.6
April 23, 2026	FTC announces an agreement in principle with USAP itself, intended to restore a competitive market structure in Texas; the commission voted 2-0 to authorize the settlement and a stay of litigation while USAP carries it out. If USAP does not follow through, the FTC says it will return to court.7

As of the newest source found for this article, the USAP case is stayed, the settlement terms are not public, and the FTC has said it will resume litigation if USAP does not complete the agreed relief.⁷ Confirm the current docket status with counsel: a case like this can move between the writing of an article and your reading it.

A state case that already reached a remedy

Colorado's case against USAP settled sooner, and shows what a remedy can look like. In February 2024, Colorado Attorney General Phil Weiser alleged that USAP had acquired independent practices to eliminate competition in the Denver market, used exclusive contracts to lock in hospital relationships, and negotiated reimbursement rates well above competitors' rates. Under the agreement announced on February 27, 2024, USAP agreed to divest its exclusive contracts at five Colorado hospitals, including St. Anthony Hospital and Mercy Hospital in Durango, and to pay $200,000, among other terms.⁸

Keep two things separate. The allegations describe conduct in one state, not a verdict on private equity ownership generally. And a settlement is not an admission the allegations were true, only an agreement on set terms.

What the research finds on price

Litigation tells you what regulators allege. A 2022 study in JAMA Internal Medicine looked at what actually happened to prices. Researchers examined more than 2.25 million privately insured anesthesia claims from 2012 through 2017, comparing facilities that signed with a physician management company against facilities that did not. After a management company contract began, prices rose 16.5% overall: 26.0% where the management company had private equity backing, and 12.9% where it did not. The study found no evidence that anesthesia practitioners moved out of network as a result.⁹

That gap, roughly double the price growth under private equity ownership compared with non-PE management, is evidence that ownership structure, and not only scale, can affect what a hospital's payers and patients pay. It does not predict what will happen at any single hospital. Payer mix, local competition and contract terms all still matter, and our look at why anesthesia subsidies keep rising covers the other forces pushing the same number up regardless of who owns the group.

What a consolidated market does to your position at the table

Set the litigation and the research next to each other and the practical risk comes into focus. A market with one dominant regional group, instead of several competing ones, gives that group more room to set the terms of the next renewal, because you have fewer credible alternatives to point to. An exclusivity clause that made sense with a small local group can become a lever a much larger platform uses to hold every site in your system at once. A request for proposals that draws one bid from the only sizable group in your region is not much of a request for proposals. Our RFP guide and our transition plan for changing groups both assume a competitive process is possible; a consolidated market is where that assumption gets tested first, not assumed.

Consolidation does not only cost hospitals money. Scale can fund what a small independent group cannot: recruiting infrastructure in a tight labor market, credentialing and scheduling systems, and the billing specialization anesthesia requires, a subject our billing explainer covers. A physician-practice-management publication puts the tradeoff plainly: a firm's ability to cut costs and grow the practices it owns is also how it produces the return its investors expect, and that alignment can run with or against a hospital's interests depending on the deal and contract terms.² Consolidation is neither a guaranteed saving nor an automatic overcharge. It is a shift in bargaining position your contract either anticipates or does not.

What to check before your next renewal or RFP

• Change of control and assignment. Does your contract require your consent, or even notice, before the group can be sold, merged or assigned to a new parent? Many older contracts are silent on this, so the group can be acquired with no obligation to tell you first.
• Notice of ownership change. Ask for advance written notice of any change of control, and a contact at the new ownership who can answer questions about staffing and rates.
• Data and audit rights. Confirm you can still see collections, staffing and payer mix after a sale. A new owner's reporting systems may differ, and rights that existed only informally with the old owner do not carry over on their own.
• Non-solicitation scope. Check how broadly the non-solicitation language reaches, and whether it would block you from hiring clinicians already in your rooms if you needed a different group later.
• An interim coverage option. Know, in advance, who could staff your rooms on short notice if a large regional group's terms become unworkable and no competing bidder exists locally. Ask a locum provider what it could realistically staff, and at what cost, before you need the answer.

Our ten questions before renewing an anesthesia contract covers the rest of the checklist, and applies whether or not your group has been acquired.

State notice laws you may not know about

A growing number of states now require notice, and sometimes approval, before a health care transaction involving a hospital-based physician group can close. A law firm tracking these laws counted at least 15 states with some form of health care transaction review, including Oregon, Colorado, Massachusetts, Illinois, Connecticut, Washington and New York, several of which recently broadened their laws to cover private equity investments specifically. New Mexico's 2025 law requires 120 days' pre-closing notice to, and approval from, its Health Care Authority.¹⁰ Oregon's Health Care Market Oversight program reviews proposed transactions among health care entities for their effect on cost, access, quality and market concentration before they close.¹¹

These laws govern the transaction between buyer and seller, not your contract with the group. But where one exists, it is a source of information you would not otherwise have: some states publish notice filings that can tell you a deal is underway before your group's new owner calls to introduce themselves. Ask counsel whether your state runs a review program, and whether its filings are public.

The state of play, plainly

Private equity ownership of an anesthesia group is not, by itself, a reason to distrust the clinicians covering your rooms, and a hospital facing a large regional platform is not powerless. What changes is how much preparation a renewal or an RFP needs, and how much your contract's fine print, on assignment, notice, data rights and non-solicitation, has to do the work a competitive local market used to do for you. Our anesthesia contract negotiation work starts with that fine print, and with a clear picture of who else could realistically staff your rooms if the group you have today is not the group you have in three years.

Sources

1. Loren Adler, Conrad Milhaupt and Samuel Valdez, "Measuring private equity penetration and consolidation in emergency medicine and anesthesiology," Health Affairs Scholar, June 2023. https://academic.oup.com/healthaffairsscholar/article/1/1/qxad008/7203733 ↩

2. Joe Aguilar and Natalie Bell, "Knock, knock... Who's there? Considerations for when private equity comes for physician acquisitions," MGMA, January 2024. https://www.mgma.com/articles/considerations-for-when-private-equity-comes-for-physician-acquisitions ↩ ↩²

3. Federal Trade Commission, "FTC Challenges Private Equity Firm's Scheme to Suppress Competition in Anesthesiology Practices Across Texas," FTC Press Release, September 2023. https://www.ftc.gov/news-events/news/press-releases/2023/09/ftc-challenges-private-equity-firms-scheme-suppress-competition-anesthesiology-practices-across ↩ ↩²

4. Greenberg Traurig, "FTC Sues Private Equity Fund and U.S. Anesthesia Partners Over Alleged 'Roll Up' Acquisitions, 'Anticompetitive Scheme,'" Greenberg Traurig Insights, October 2023. https://www.gtlaw.com/en/insights/2023/10/ftc-sues-private-equity-fund-and-us-anesthesia-partners-over-alleged-roll-up-acquisitions-anticompetitive-scheme ↩

5. Goodwin Procter, "District Court Grants Welsh Carson's Motion to Dismiss in FTC's 'Roll-Up' Monopolization Case; Case Against U.S. Anesthesia Partners Continues," Goodwin Insights & Resources, May 2024. https://www.goodwinlaw.com/en/insights/publications/2024/05/alerts-privateequity-hltc-district-court-grants-welsh-carsons-motion ↩

6. Federal Trade Commission, "FTC Secures Settlement with Private Equity Firm in Antitrust Roll-Up Scheme Case," FTC Press Release, January 2025. https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case ↩

7. Federal Trade Commission, "FTC Charts Path to Restore Competition in Texas Anesthesia Markets in USAP Litigation," FTC Press Release, April 2026. https://www.ftc.gov/news-events/news/press-releases/2026/04/ftc-charts-path-restore-competition-texas-anesthesia-markets-usap-litigation ↩ ↩²

8. Colorado Attorney General, "Private equity-run U.S. Anesthesia Partners to end Colorado health care monopoly under agreement with Attorney General Phil Weiser," press release, February 2024. https://coag.gov/press-releases/usap-health-care-monopoly-attorney-general-phil-weiser-2-27-2024/ ↩

9. Ambar La Forgia, Amelia M. Bond, Robert Tyler Braun, et al., "Association of Physician Management Companies and Private Equity Investment With Commercial Health Care Prices Paid to Anesthesia Practitioners," JAMA Internal Medicine, February 2022. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789280 ↩

10. DLA Piper, "A growing state of oversight: How states are continuing to reshape (and restrict) healthcare transactions and private equity investment in healthcare in 2025," DLA Piper Insights, June 2025. https://www.dlapiper.com/en/insights/publications/2025/06/states-impact-on-healthcare-transactions-and-private-equity-investment-2025 ↩

11. Oregon Health Authority, "Health Care Market Oversight," Oregon.gov, undated. https://www.oregon.gov/oha/hpa/hp/pages/health-care-market-oversight.aspx ↩